Yuichiro Haruyama serves as Chief Financial Officer and a member of the board of Sumitovant Biopharma. Mr. Haruyama was instrumental in creating the broad strategic partnership between Sumitomo Pharma and Roivant Sciences in 2019, including forming Sumitovant Biopharma. He started his career at Sumitomo Chemical, a leading Japanese chemical company, in 1993 and, since then, he has played a leading role in global pharmaceutical/chemical operations, corporate strategy, business development and finance. At Sumitomo Chemical, he was responsible for designing and implementing strategy for OLED (organic light-emitting diode) business, including a number of partnerships with global electronics companies, as well as oversaw its global operations. At Sumitomo Pharma, he served as a key member in developing the corporate mid-term business plan in 2019, setting up and managing global business operations, such as the U.S., UK and Chinese affiliate companies, and leading a number of M&A efforts. Mr. Haruyama earned a Bachelor of Science degree in Business and Commerce at Keio University in Tokyo and an MBA in finance from Indiana University in Bloomington, Indiana.
Tara Soni serves as General Counsel at Sumitovant. Ms. Soni has served as a Partner on the Legal Team of Roivant Sciences since July 2016 where she held a diverse role that focused on corporate transactions, compliance, employment law and general corporate advisory work. She previously served as Assistant General Counsel to a financial technology firm where she led the legal function across multiple jurisdictions in Europe, North America and South America. She began her career as an attorney specializing in cross-border transactions, with a focus on emerging markets. Ms. Soni is a dual-qualified attorney and is licensed to practice law in New York and India. She holds a LL.B. (Juris Doctor equivalent) from University of Delhi and an LL.M. from New York University School of Law.
Mi Yong Cho serves as the Chief People Officer at Sumitovant. In this role, she is responsible for overseeing the firm’s people strategy and operations, including recruiting, talent development, and total rewards. Ms. Cho has served as the Head of Human Resources at Roivant Sciences since August 2018, where she transformed the Human Resources department from a service provider to a strategic business partner. Prior to joining Roivant, Ms. Cho spent eight years at Two Sigma Investments, where she founded and led the compensation, talent analytics and HR infrastructure teams and served in various HR leadership roles. Previously, she held multiple HR and compensation roles at Credit Suisse and Merrill Lynch. Ms. Cho began her career in investment banking and received her B.A. in Economics and M.B.A. from Columbia University.
Bill McMahon serves as Chief Algorithmic Analytics Officer of Sumitovant. McMahon served as Vice President of Computation Research at Roivant Sciences since 2016 during which time he led the development of the DrugOme. From 2009-2016, McMahon was the manager and technical lead of the functional reliability team at GlobalFoundries responsible for critical semiconductor process technologies. Previously McMahon held multiple Senior Engineer and Physicist roles at Numonyx, Intel, and Data Storage Institute. McMahon received his B.S. degrees in Electrical Engineering, Computer Science, and Physics from MIT and a Ph.D. in Physics from the University of Illinois at Urbana-Champaign.
Dan Rothman currently serves in dual leadership roles as Chief Information Officer for Sumitovant Biopharma and Chief Digital Officer for parent company Sumitomo Pharma where he has built an entire digital ecosystem across both organizations. This includes establishing platforms such as data engineering and DevOps, building a digital strategy team, and leading enterprise technology and infrastructure, all designed to unlock new value through novel applications of technology. His team has doubled in size annually since inception and identified more than 50 solutions that improve drug discovery, accelerate clinical trials and improve commercialization. Previously he was the Chief Information Officer for Roivant Sciences.
Dan is an innovative leader with a proven track record of leveraging technology to drive digital and behavioral transformation across businesses. He is highly skilled at building and inspiring teams to achieve organizational growth through technology and has specific expertise in applying technology to traditional sectors including healthcare and finance.
Dan’s approach to applied technology has been formed through his unique career journey. After graduating with bachelor’s and master’s degrees in electrical engineering and computer science from MIT, Dan spent a brief time in Silicon Valley as a computer chip designer before embarking on a 20-year career in finance with firms including Goldman Sachs and Lehman Brothers. During this time, he built trading, sales and analytics businesses and revolutionized them with the application of new technology approaches. Dan carried these learnings to his career in pharmaceuticals, looking for opportunities where technology can disrupt how value is created and how to solve business problems through existing methodologies applied in alternate ways.
Adele Gulfo is Chief Commercial and Business Development Officer at Sumitovant. Gulfo is a member of the Board of Directors of Myovant Sciences, a majority-owned company of Sumitovant Biopharma, and served as the company’s interim CCO from May 2020 to May 2021. Before joining Sumitovant, Gulfo served as Chief of Commercial Development at Roivant Sciences. Previously Gulfo served as President and General Manager of Pfizer’s $12B+ US primary care business unit, comprised of over 5,000 employees across multiple therapeutic areas. She also ran Pfizer’s Commercial Operations, and as US Country Chair led the Managed Care organization across all biopharmaceutical businesses, including Specialty, Oncology, and Vaccines. She ran the Latin America biopharmaceutical business for Pfizer including primary care, oncology, rare disease and vaccines across 23 countries. During this time, revenue grew while reducing expenses. Gulfo has over 25 years of experience in the bio pharmaceutical industry and also held executive level roles at Mylan and AstraZeneca. She has experience launching and growing many well-known blockbuster brands including Crestor, Lipitor, Viagra, Celebrex, Lyrica, Premarin and Eliquis. Gulfo also serves on the boards of Medexus Pharma and Enpro Industries. She received a BS in Biology and Chemistry and MBA in Marketing from Seton Hall University. Gulfo also received an MBA with a Pharma emphasis from Fairleigh Dickinson University and trained in Post Grad Molecular Biology at the University of Medicine and Dentistry of New Jersey.
Salomon Azoulay, M.D., serves as the Chief Medical Officer and Head of Research & Development of Sumitovant. In this role he oversees numerous functions including clinical development, CMC, Regulatory, and medical affairs functions. Dr. Azoulay previously served as Chief Medical Officer of Roivant Sciences. He joined Roivant from Pfizer, where he most recently served as Senior Vice President and Chief Medical Officer for Pfizer Essential Health. In that role he oversaw clinical development and medical affairs for a portfolio that included over 600 branded products as well as biosimilars and sterile injectables. He has over 25 years of experience in the biopharmaceutical industry and held senior leadership roles at Pfizer since 2001, including Head of Development in Japan and Senior Vice President for Medical and Development in Emerging Markets.
Industry trailblazer, Myrtle Potter assumes the role of CEO for Sumitovant after having served as Vant Operating Chair of Roivant Sciences since 2018. In that role she oversaw thirty-five investigational drugs in eleven therapeutic areas being tested in over fifty clinical trials across the Roivant family of companies. She brings a proven track record of building and leading high-performance teams to bring successful drugs to market. As CEO of Myrtle Potter & Company she and her 150+ hand-picked team of experts led major strategic efforts and multiple product launches for numerous biopharmaceutical companies. As President and COO and of Genentech, she oversaw 5X revenue growth in 5 years to $5 billion resulting in record sales and earnings growth for 19 of 20 consecutive quarters. Prior to joining Genentech, she served as president of Bristol-Myers Squibb’s $4 billion, 3,500-person U.S. Cardiovascular/Metabolics business. While at Merck she started the company Astra-Merck which later, through a series of transactions became Astra-Zeneca. Potter is a graduate of the University of Chicago and serves on the university’s board of trustees. She also serves on the board of Liberty Mutual Insurance Group, and has served on the boards of Amazon, Axsome Therapeutics, Express Scripts and Medco.